Pathos AI raises $237M from Bristol Myers Squibb to point its AI agents at Alzheimer's

• Who: Pathos AI, a New York-based clinical-stage AI and biotech company
• What: $237M Series E led by Bristol Myers Squibb at a ~$3B post-money valuation, plus multi-year collaborations with BMS and Tempus AI
• When: Announced Friday, October 23, 2026
• Data deal: Tempus builds a de-identified dataset from hundreds of thousands of neuro patients; Pathos licenses it for $55M over five years
• BMS terms: Non-exclusive Foundry access across its portfolio, plus three-year exclusive rights for neuroscience programs
• Backstory: Total funding ~$704M; $365M Series D at ~$1.6B (May 2025); $62M Series C at $600M (Oct 2024); pipeline includes JSKN016 (licensed from Alphamab for $125M upfront + up to $2.09B milestones)

Pathos AI is taking the AI platform that powered its cancer pipeline and pointing it at the brain. The New York-based clinical-stage biotech announced Friday a $237 million Series E led by Bristol Myers Squibb at a roughly $3 billion valuation — bundled with multi-year collaborations with BMS and Tempus AI to build AI drug-development tools for Alzheimer’s disease and other neurological conditions.

The deals

The centerpiece is data. Tempus AI will apply the infrastructure it built in oncology to assemble a comprehensive, de-identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, designed to track outcomes over time and accelerate biological insight. Pathos will license the dataset under a five-year, $55 million agreement, Reuters reported.

Pathos will then apply its agentic AI platform, Pathos Foundry, to interrogate that dataset at scale — generating and testing hypotheses on disease biology and informing the design of more targeted, adaptive clinical trials. Bristol Myers Squibb gets non-exclusive strategic access to Foundry across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programs.

Foundry goes to the brain

The bet is that a system validated in oncology can transfer to neurology. Pathos built Foundry around thousands of AI agents that study data on diseases, patients, and clinical trials, and the company says it already guides decisions across its clinical-stage cancer pipeline — including adapting trial design in real time to improve projected probability of success.

That pipeline currently lists four clinical-stage cancer drugs: pocenbrodib for prostate cancer and multiple myeloma, DO-2 for a type of lung cancer, P-100 for breast cancer — developed with AstraZeneca — and JSKN016 for solid tumors. Pathos licensed JSKN016 from China’s Alphamab Oncology in August in a deal worth $125 million upfront and up to $2.09 billion in milestone payments, The Latent reported.

The money trail

The $237 million round, with participation from existing investors, brings Pathos’s total funding to about $704 million. It follows a $365 million Series D at a roughly $1.6 billion post-money valuation in May 2025 and a $62 million Series C at a $600 million valuation in October 2024. Earlier backers include New Enterprise Associates, Revolution Growth, Lightbank, and Builders VC.

Proceeds will go toward scaling Foundry’s capabilities and advancing the AI-driven pipeline — including JSKN016 and the AstraZeneca-partnered breast cancer program. The message from the announcement is blunt: after proving its agents in oncology, Pathos now wants the brain. With a $55 million dataset, a pharma giant’s checkbook, and exclusive neuroscience rights on the line, the next few years will show whether agentic AI can do for neurology what it has started to do for cancer.